Introduction of Non-surgical Treatments to Propel BCC Treatment Market at 9% CAGR
Delay in basal cell carcinoma (BCC) treatment can lead to complications regarding the skin, muscle, and even bone damage. Hence, patients suffering from BCC are opting for non-surgical treatments such as superficial radiation therapy (SRT), since this treatment is associated with fewer complications. SRT is gaining increased popularity in the basal cell carcinoma treatment market.
This is because conventional radiotherapy treatment has become impractical for dermatologists. Large obsolete machines for conventional SRT are difficult to maintain and are challenging to operate for the average community dermatologist.
The basal cell carcinoma treatment market is projected for high growth with the introduction of modernized SRT. This growth is further catalyzed with healthcare providers combining SRT with Mohs surgery for the effective treatment of BCC.
SRT leads to better patient outcomes, as the treatment only affects the cancer cells, thus allowing the healthy cells to survive and rejuvenate. Healthcare companies in the basal cell carcinoma treatment market can capitalize on this highly-lucrative segment by increasing the availability of SRT in hospitals and specialty clinics.
SRT can help companies expand their incremental opportunities, as it can be used for the treatment of other non-melanomas cancers such as squamous cell carcinoma.
Know More Details About the Report
Companies Experimenting with Dosing Regimens of Hedgehog Pathway Inhibitor Drugs for Treatment of BCC
Healthcare companies in the basal cell carcinoma treatment landscape are developing improved formulations of drugs to reduce the incidence of basal cell carcinoma.
As such, drugs account for the second-highest revenue amongst all treatment options in the basal cell carcinoma treatment market, with a projected value of US$ 2.3 billion by the end of 2025.
Apart from surgical and other treatment options, drugs are expected to experience exponential growth in adoption during the forecast period of 2020–2025. Healthcare companies in the basal cell carcinoma treatment market are introducing hedgehog pathway inhibitors, a novel drug class for the treatment of basal cell carcinoma.
Since BCC is one of the most common cancers in the U.S, companies are increasing production capacities to manufacture hedgehog pathway inhibitor drugs in this region.
However, the drug is associated with adverse effects in patients, such as muscle spasms and drug-resistance. Hence, companies in the basal cell carcinoma treatment market are assessing the dosing regimens for the effective BCC treatment.
Avail customized purchase options for your needs
Radiotherapy and Emergence of CROs Trigger Market Growth
North America and Asia Pacific are anticipated to exhibit high growth potential in the basal cell carcinoma treatment market. North America alone is expected to generate a revenue of US$ 5.8 billion by 2025, and retain its dominance in the market. Increasing awareness about BCC and its improved treatment options have triggered market growth in the region.
The Skin Cancer Foundation is a global organization that strives to create awareness about BCC, and aims to continue its fellowship training program to teach the right techniques of Mohs surgery to dermatologists.
Asia Pacific is projected to account for the third-highest revenue amongst all regions in the global basal cell carcinoma treatment market. The emergence of new contract research organizations that offer valuable insights on various dermatological treatments to healthcare providers is catalyzing growth in the market landscape.
This trend is aiding the strengthening of the healthcare infrastructure in various countries of the Asia Pacific region.
An Adaptive Approach to Modern-day Research Needs
Basal Cell Carcinoma Treatment Market – Assessment of Key Segments
With an aim to offer granular level insights into the basal cell carcinoma treatment market, authors of the report have segmented the landscape on the basis of treatment, end user, and region.
This global research report also throws light on the incremental opportunities available in the basal cell carcinoma treatment market landscape during the forecast period. Key segments of the basal cell carcinoma treatment market include:
This detailed guide, based on the latest market movement, ensures that only precise information reaches stakeholders, so as to help them gain an upper hand over their competitors in the global basal cell carcinoma treatment market.
This exclusive guide offers crucial information about the current trends, future scope, and government regulations for the basal cell carcinoma treatment market.
Basal Cell Carcinoma Treatment Market – Scope of the Study
Fact.MR, in its exclusive research report on the basal cell carcinoma treatment market, highlights actionable insights and winning imperatives for stakeholders. This comprehensive study unfolds rare and distinguished intelligence regarding impactful dynamics, which directly or indirectly influence the growth of the basal cell carcinoma treatment market during the forecast period (2020-2025).
With the help of important insights discussed in this study, stakeholders will gain a thorough idea regarding the growth projection of the basal cell carcinoma treatment market.
This comprehensive study offers incisive data regarding the drivers, threats, restraints, and opportunities present in the basal cell carcinoma treatment market. The study also assesses the impact of each of these dynamics to estimate the size of the basal cell carcinoma treatment market for the given period.
Authors of the report have taken ample care to measure and include the relevance and impact of microeconomic as well as macroeconomic factors that hold potential to influence the growth of the basal cell carcinoma treatment market during the forecast period.
The global study on the basal cell carcinoma treatment market includes Porter’s Five Forces analysis, in order to present the buyer’s and supplier’s power in the basal cell carcinoma treatment landscape. In addition, the analysis also discusses the threat of substitutes and new drug entrants, which provides a brief idea regarding the future growth course of the basal cell carcinoma treatment market.
The global study offers crucial information about global, regional, and local players operating in the basal cell carcinoma treatment market, along with their estimated market share, which has been estimated in terms of value (US$ Mn).
Besides providing key information regarding the concentration of leading, prominent, and local players, the study also aims at educating stakeholders with the best of information regarding winning strategies, recent developments, and financials.
This comprehensive study also contains detailed insights of the players present in the basal cell carcinoma treatment market, which include Valeant Pharmaceuticals International, Inc., F. Hoffmann-La Roche Ltd., Sun Pharmaceuticals Ltd., Mylan N.V., and Merck & Co., Inc.
Basal Cell Carcinoma Treatment Market – Research Methodology
Research undertaken by seasoned analysts at Fact.MR consists of a systematic approach. A combination of the bottom-up and top-down approach is leveraged to estimate the size of the basal cell carcinoma treatment market.
Besides this, primary and secondary research studies are carried out through credible sources to acquire crucial insights into the basal cell carcinoma treatment market. For conducting primary research, interviews and discussions were carried out with industry experts, vendors, key opinion leaders, and distributors.
Besides these, respondents also include CEOs, presidents, directors, chairmen, vice presidents, marketing managers, suppliers, distributors, and chief medical officers, among others. This helps in assessing the demand-supply gap prevailing in the basal cell carcinoma treatment market.
In order to conduct secondary research, marketing collaterals, company websites, industry associations, and government statistics were studied. In addition to this, reports as well as content pieces published by credible sources, such as company annual reports, investor presentations, and SEC-filings were studied.
Need an Exclusive Report for your Unique Requirement?
- Our Clients -
- Evaluate How Fact.MR's Report Can Help. -
Is the market research conducted by Fact.MR?
Yes, the report has been compiled by expert analysts of Fact.MR, through a combination of primary and secondary research. To know more about how the research was conducted, you can speak to a research analyst.
What research methodology is followed by Fact.MR?
Fact.MR follows a methodology that encompasses the demand-side assessment of the market, and triangulates the same through a supply-side analysis. This methodology is based on the use of standard market structure, methods, and definitions.
What are the sources of secondary research?
Fact.MR conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
Who are the respondents for primary research?
Fact.MR speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, and industry experts. For a full list of primary respondents, please reach out to us.
Is a sample of this report available for evaluation?
Yes, you can request a sample, and it will be sent to you through an email.